Master the safe and effective use of obesity medications with Endocrinologist, Dr. Karl Nadolsky (co-author of 2016 AACE Obesity guidelines), Director of the Diabetes, Obesity & Metabolic Institute at Walter Reed National Military Medical Center. We get under the hood of each FDA approved obesity medication plus some of our normal hijinks. Check out episode #23 for a more general overview of obesity.

Full show notes available at http://thecurbsiders.com/podcast

Join our newsletter mailing list. Rate us on iTunes, recommend a guest or topic and give feedback at thecurbsiders@gmail.com.

Time Stamps

00:00 Intro

03:12 Picks of the week

08:44 Rapid fire questions

13:00 Counsel patients about obesity

14:40 Pathophysiology of obesity

18:00 Case

22:46 Phentermine/topiramate (Qsymia)

26:20 Bupropion/naltrexone (Contrave)

29:18 Liraglutide (Saxenda)

34:32 Orlistat (Alli, Xenical)

37:35 Cost issues

40:18 Lifelong medical therapy for obesity

42:44 Dr. Nadolsky’s take home points

44:45 The Curbsiders recap and discuss their experience with obesity medications

52:28 Outro

Tags: assistant, care, doctor, education family, foam, foamed, health, hospitalist, hospital, internal, internist, nurse, medicine, medical, physician, practitioner, primary, resident, student, obesity, pharmacotherapy, weight loss, safety, side effects, orlistat, alli, naltrexone, bupropion, contrave, phentermine, topiramate, qsymia, lorcaserin, belviq, FDA

#44: Obesity Medication Overview from AACE 2017

The Curbsiders Internal Medicine Podcast